HeimEVGN • NASDAQ
add
Evogene Ltd
0,79 $
Eftir lokun(2,72%)+0,021
0,81 $
Lokað: 5. mar., 18:00:01 GMT-5 · USD · NASDAQ · Lagalegir fyrirvarar
Við síðustu lokun
0,84 $
Dagbil
0,73 $ - 0,84 $
Árabil
0,73 $ - 2,42 $
Markaðsvirði
6,84 m. USD
Meðalmagn
835,28 þ.
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
NASDAQ
Í fréttum
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (USD) | sep. 2025info | Breyting á/á |
|---|---|---|
Tekjur | 312,00 þ. | -82,63% |
Rekstrarkostnaður | 2,88 m. | -64,76% |
Nettótekjur | 3,87 m. | 150,77% |
Hagnaðarhlutfall | 1,24 þ. | 392,27% |
Hagnaður á hvern hlut | -0,46 | 64,51% |
EBITDA | -2,44 m. | 64,22% |
Virkt skatthlutfall | -0,04% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (USD) | sep. 2025info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 15,96 m. | -20,02% |
Heildareignir | 26,09 m. | -34,97% |
Heildarskuldir | 8,83 m. | -68,31% |
Eigið fé alls | 17,25 m. | — |
Útistandandi hlutabréf | 8,72 m. | — |
Eiginfjárgengi | 6,45 | — |
Arðsemi eigna | -22,70% | — |
Ávöxtun eigin fjár | -39,13% | — |
Peningaflæði
Breyting á handbæru fé
| (USD) | sep. 2025info | Breyting á/á |
|---|---|---|
Nettótekjur | 3,87 m. | 150,77% |
Handbært fé frá rekstri | -3,33 m. | 32,37% |
Reiðufé frá fjárfestingum | 10,91 m. | 441,12% |
Reiðufé frá fjármögnun | -10,34 m. | -318,34% |
Breyting á handbæru fé | -2,70 m. | -247,46% |
Frjálst peningaflæði | -385,62 þ. | -131,18% |
Um
Evogene is a computational chemistry company based in Israel, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries. At the core of its technology is ChemPass AI, a proprietary generative AI engine that enables the design of novel, highly potent small molecules optimized across multiple critical parameters. This powerful platform significantly improves success rates while reducing development time and costs. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products driven by the integration of scientific innovation with real-world industry needs.
In 2024, the company began collaborating with Google Cloud to develop an AI-powered generative model aimed at discovering small molecules for drug development and sustainable agriculture. Wikipedia
Framkvæmdastjóri
Stofnsett
1999
Vefsvæði
Starfsfólk
117
